FDA ‘breakthrough’ status for synthetic meniscus bodes well for Memphis’ Active Implants
“Instead of going through our process and filing what we think the FDA wants from us, we enter a phase called the sprint interface,” said Ted Davis, president and CEO Active Implants, “for an ongoing review of our progress in real time. We believe it will help us be more efficient and shorten the time to work through the approval process.” (Mark Weber/Daily Memphian)
Active Implants’ president and CEO hopes to shave time off the FDA approval process for the company's synthetic meniscus device.
Topics
breakthrough device designation Dr. Tom Geil FDA Ted DavisJane Roberts
Jane Roberts has reported in Memphis for more than 20 years. As a senior member of The Daily Memphian staff, she was assigned to the medical beat during the COVID-19 pandemic. She also has done in-depth work on other medical issues facing our community, including shortages of specialists in local hospitals. She covered K-12 education here for years and later the region’s transportation sector, including Memphis International Airport and FedEx Corp.
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.